Bedside to Bench: Integrating Quantitative Clinical Pharmacology and Reverse Translation to Optimize Drug Development

Por Gibbs, John P., Menon, Rajeev, Kasichayanula, Sreeneeranj
Publicado no Clin Pharmacol Ther (2017)

Assessment of pharmacokinetic interaction between rilotumumab and epirubicin, cisplatin and capecitabine (ECX) in a Phase 3 study in gastric cancer

Por Zhang, Yilong, Kuchimanchi, Mita, Zhu, Min, Doshi, Sameer, Hoang, Tien, Kasichayanula, Sreeneeranj
Publicado no Br J Clin Pharmacol (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor

Por Kasichayanula, Sreeneeranj, Grover, Anita, Emery, Maurice G., Gibbs, Megan A., Somaratne, Ransi, Wasserman, Scott M., Gibbs, John P.
Publicado no Clin Pharmacokinet (2018)

Simultaneous oral therapeutic and intravenous (14)C‐microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin

Por Boulton, David W., Kasichayanula, Sreeneeranj, Keung, Chi Fung (Anther), Arnold, Mark E., Christopher, Lisa J., Xu, Xiaohui (Sophia), LaCreta, Frank
Publicado em 2013

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus

Por Kasichayanula, Sreeneeranj, Liu, Xiaoni, Pe Benito, Melanie, Yao, Ming, Pfister, Marc, LaCreta, Frank P, Humphreys, William Griffith, Boulton, David W
Publicado em 2013

Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects

Por Kasichayanula, Sreeneeranj, Boulton, David W, Luo, Wen-Lin, Rodrigues, A David, Yang, Zheng, Goodenough, Angela, Lee, Michelle, Jemal, Mohammed, LaCreta, Frank
Publicado no Br J Clin Pharmacol (2014)

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety

Por Lee, Edward, Gibbs, John P., Emery, Maurice G., Block, Geoffrey, Wasserman, Scott M., Hamilton, Lisa, Kasichayanula, Sreeneeranj, Hanafin, Patrick, Somaratne, Ransi, Egbuna, Ogo
Publicado no Clin Pharmacol Drug Dev (2019)

Crowdsourced Asparagus Urinary Odor Population Kinetics

Por Ramamoorthy, Anuradha, Sadler, Brian M., van Hasselt, J.G. Coen, Elassaiss‐Schaap, Jeroen, Kasichayanula, Sreeneeranj, Edwards, Alena Y., van der Graaf, Piet H., Zhang, Lei, Wagner, John A.
Publicado no CPT Pharmacometrics Syst Pharmacol (2017)

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

Por DeFronzo, Ralph A., Hompesch, Marcus, Kasichayanula, Sreeneeranj, Liu, Xiaoni, Hong, Ying, Pfister, Marc, Morrow, Linda A., Leslie, Bruce R., Boulton, David W., Ching, Agatha, LaCreta, Frank P., Griffen, Steven C.
Publicado em 2013

Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)

Por Powderly, John, Spira, Alexander, Kondo, Shunsuke, Doi, Toshihiko, Luke, Jason J., Rasco, Drew, Gao, Bo, Tanner, Minna, Cassier, Philippe A., Gazzah, Anas, Italiano, Antoine, Tosi, Diego, Afar, Daniel E., Parikh, Apurvasena, Engelhardt, Benjamin, Englert, Stefan, Lambert, Stacie L., Kasichayanula, Sreeneeranj, Mensing, Sven, Menon, Rajeev, Vosganian, Gregory, Tolcher, Anthony
Publicado no Clin Transl Sci (2020)